Daniela Zantomio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniela Zantomio has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Efstratios Skafidas
Department of Electrical and Electronic Engineering Faculty of Engineering and Information Technology The University of Melbourne Parkville VIC 3010 Australia
2 shared publications - Gursharan Chana
Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Victoria, Australia.
2 shared publications Masa Lasica
Clinical Haematology Department, Austin Health, Victoria, Australia
2 shared publicationsAllison Mo
1 shared publicationAndrew Spencer
Department of Haematology and Bone Marrow Transplant Alfred Health Melbourne Victoria Australia
1 shared publication- Benjamin Goudey
ARC Training Centre in Cognitive Computing for Medical Technologies University of Melbourne Carlton Victoria Australia
1 shared publication
Latest Publications
- 4 August 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (4) , e70164
A Case of Vanished Buffy Coat in Peripheral Blood Hematopoietic Progenitor Cell Harvest
We report on an autologous hematopoietic progenitor cell collection via apheresis (HPC(A)) with adequate CD34+ pre‐count and unexpectedly low collection efficiency resulting in a failed HPC(A) collection. The collection bag contained almost no buffy coat and the plasma was orange. We assess both collection and patient factors that may have contributed to this finding.
- 4 August 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (4) , e70164
A Case of Vanished Buffy Coat in Peripheral Blood Hematopoietic Progenitor Cell Harvest
We report on an autologous hematopoietic progenitor cell collection via apheresis (HPC(A)) with adequate CD34+ pre‐count and unexpectedly low collection efficiency resulting in a failed HPC(A) collection. The collection bag contained almost no buffy coat and the plasma was orange. We assess both collection and patient factors that may have contributed to this finding.
- Open Access
- 7 July 2026
- Published by Wiley in Internal Medicine Journal
- Vol. 56 (7) , 1245-1249
Limited lenalidomide exposure and access to rescue plerixafor can eliminate haemopoietic progenitor cell first collection failure in bortezomib, lenalidomide and dexamethasone treated transplant eligible multiple myeloma patients
This retrospective single‐centre study assessed sequential strategies to improve the success rate for haemopoietic progenitor cell mobilisation in multiple myeloma. Transplant‐eligible multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone experience a mobilisation failure rate of 32%. We show that a combination of limiting lenalidomide exposure to less than 6 weeks and access to rescue plerixafor can eliminate haemopoietic progenitor cell collection failure without compromising other collection parameters.
- 7 July 2026
- Published by Wiley in Internal Medicine Journal
- Vol. 56 (7) , 1245-1249
Open AccessLimited lenalidomide exposure and access to rescue plerixafor can eliminate haemopoietic progenitor cell first collection failure in bortezomib, lenalidomide and dexamethasone treated transplant eligible multiple myeloma patients
This retrospective single‐centre study assessed sequential strategies to improve the success rate for haemopoietic progenitor cell mobilisation in multiple myeloma. Transplant‐eligible multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone experience a mobilisation failure rate of 32%. We show that a combination of limiting lenalidomide exposure to less than 6 weeks and access to rescue plerixafor can eliminate haemopoietic progenitor cell collection failure without compromising other collection parameters.
- Open Access
- 15 October 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (2) , 291-303
Human leukocyte antigen sensitization from red cell transfusions: Rate and risk factors in renal and nonrenal patients requiring transfusion
- 15 October 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (2) , 291-303
Open AccessHuman leukocyte antigen sensitization from red cell transfusions: Rate and risk factors in renal and nonrenal patients requiring transfusion
- 2 September 2022
- Published by Wiley in Internal Medicine Journal
- Vol. 53 (5) , 717-722
Centre‐based comparison of double versus single prevention strategy on transfusion‐transmitted cytomegalovirus in at‐risk haemopoietic stem cell transplant patients and a state survey on cytomegalovirus‐seronegative ordering practises
Background Universal leucocyte depletion reduces the risk of transfusion-transmitted cytomegalovirus; however, many clinicians still prescribe cytomegalovirus seronegative units. Aim Our retrospective study aims to confirm the low risk of transfusion-transmitted cytomegalovirus with leucocyte depletion alone and demonstrate the ongoing variability in cytomegalovirus seronegative transfusion prescribing. Methods Over a 9-year period (July 2009-July 2018), occurrences of transfusion transmitted cytomegalovirus in cytomegalovirus seronegative donor/recipient haemopoietic stem cell transplant pairs were compared at one allogeneic haemopoietic stem cell transplant centre providing cytomegalovirus seronegative blood products and leucocyte depletion (double prevention) versus another providing leucocyte depletion only (single prevention). Retrospective chart audit identified patient demographics, blood product exposure and cytomegalovirus infection by polymerase chain reaction. A separate audit examined cytomegalovirus seronegative blood product ordering in a broader range of hospital types. Results We identified 122 and 66 cytomegalovirus-negative donor/recipient haemopoietic stem cell transplant pairs using double and single transfusion prevention strategy respectively. Transfusion exposure to red cells and pooled platelets was similar, although more apheresis platelets were used in the double prevention group. The cytomegalovirus infection rate was 3 (2.4%) and zero in the double and single prevention groups respectively. Cytomegalovirus seronegative unit ordering was not limited to hospitals with obstetric or neonatal populations, suggesting ongoing reliance of cytomegalovirus seronegative units outside this population. Conclusions The analysis suggests a double prevention strategy does not provide additional protection against transfusion-transmitted cytomegalovirus. There is ongoing variability in the acceptance of leucocyte depletion alone despite the low risk of cytomegalovirus infection.
- 2 September 2022
- Published by Wiley in Internal Medicine Journal
- Vol. 53 (5) , 717-722
Centre‐based comparison of double versus single prevention strategy on transfusion‐transmitted cytomegalovirus in at‐risk haemopoietic stem cell transplant patients and a state survey on cytomegalovirus‐seronegative ordering practises
Background Universal leucocyte depletion reduces the risk of transfusion-transmitted cytomegalovirus; however, many clinicians still prescribe cytomegalovirus seronegative units. Aim Our retrospective study aims to confirm the low risk of transfusion-transmitted cytomegalovirus with leucocyte depletion alone and demonstrate the ongoing variability in cytomegalovirus seronegative transfusion prescribing. Methods Over a 9-year period (July 2009-July 2018), occurrences of transfusion transmitted cytomegalovirus in cytomegalovirus seronegative donor/recipient haemopoietic stem cell transplant pairs were compared at one allogeneic haemopoietic stem cell transplant centre providing cytomegalovirus seronegative blood products and leucocyte depletion (double prevention) versus another providing leucocyte depletion only (single prevention). Retrospective chart audit identified patient demographics, blood product exposure and cytomegalovirus infection by polymerase chain reaction. A separate audit examined cytomegalovirus seronegative blood product ordering in a broader range of hospital types. Results We identified 122 and 66 cytomegalovirus-negative donor/recipient haemopoietic stem cell transplant pairs using double and single transfusion prevention strategy respectively. Transfusion exposure to red cells and pooled platelets was similar, although more apheresis platelets were used in the double prevention group. The cytomegalovirus infection rate was 3 (2.4%) and zero in the double and single prevention groups respectively. Cytomegalovirus seronegative unit ordering was not limited to hospitals with obstetric or neonatal populations, suggesting ongoing reliance of cytomegalovirus seronegative units outside this population. Conclusions The analysis suggests a double prevention strategy does not provide additional protection against transfusion-transmitted cytomegalovirus. There is ongoing variability in the acceptance of leucocyte depletion alone despite the low risk of cytomegalovirus infection.
- Open Access
- 20 July 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73 (9) , e3047-e3052
Pan-Family Assays for Rapid Viral Screening: Reducing Delays in Public Health Responses During Pandemics
Background: Coronavirus disease 2019 has highlighted deficiencies in the testing capacity of many developed countries during the early stages of pandemics. Here we describe a strategy using pan-family viral assays to improve early accessibility of large-scale nucleic acid testing. Methods: Coronaviruses and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were used as a case study for assessing utility of pan-family viral assays during the early stages of a novel pandemic. Specificity of a pan-coronavirus (Pan-CoV) assay for a novel pathogen was assessed using the frequency of common human coronavirus (HCoV) species in key populations. A reported Pan-CoV assay was assessed to determine sensitivity to 60 reference coronaviruses, including SARS-CoV-2. The resilience of the primer target regions of this assay to mutation was assessed in 8893 high-quality SARS-CoV-2 genomes to predict ongoing utility during pandemic progression. Results: Because of common HCoV species, a Pan-CoV assay would return false positives for as few as 1% of asymptomatic adults, but up to 30% of immunocompromised patients with respiratory disease. One-half of reported Pan-CoV assays identify SARS-CoV-2 and with small adjustments can accommodate diverse variation observed in animal coronaviruses. The target region of 1 well-established Pan-CoV assay is highly resistant to mutation compared to species-specific SARS-CoV-2 reverse transcriptase-polymerase chain reaction assays. Conclusions: Despite cross-reactivity with common pathogens, pan-family assays may greatly assist management of emerging pandemics through prioritization of high-resolution testing or isolation measures. Targeting highly conserved genomic regions make pan-family assays robust and resilient to mutation. A strategic stockpile of pan-family assays may improve containment of novel diseases before the availability of species-specific assays.
- 20 July 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73 (9) , e3047-e3052
Open AccessPan-Family Assays for Rapid Viral Screening: Reducing Delays in Public Health Responses During Pandemics
Background: Coronavirus disease 2019 has highlighted deficiencies in the testing capacity of many developed countries during the early stages of pandemics. Here we describe a strategy using pan-family viral assays to improve early accessibility of large-scale nucleic acid testing. Methods: Coronaviruses and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were used as a case study for assessing utility of pan-family viral assays during the early stages of a novel pandemic. Specificity of a pan-coronavirus (Pan-CoV) assay for a novel pathogen was assessed using the frequency of common human coronavirus (HCoV) species in key populations. A reported Pan-CoV assay was assessed to determine sensitivity to 60 reference coronaviruses, including SARS-CoV-2. The resilience of the primer target regions of this assay to mutation was assessed in 8893 high-quality SARS-CoV-2 genomes to predict ongoing utility during pandemic progression. Results: Because of common HCoV species, a Pan-CoV assay would return false positives for as few as 1% of asymptomatic adults, but up to 30% of immunocompromised patients with respiratory disease. One-half of reported Pan-CoV assays identify SARS-CoV-2 and with small adjustments can accommodate diverse variation observed in animal coronaviruses. The target region of 1 well-established Pan-CoV assay is highly resistant to mutation compared to species-specific SARS-CoV-2 reverse transcriptase-polymerase chain reaction assays. Conclusions: Despite cross-reactivity with common pathogens, pan-family assays may greatly assist management of emerging pandemics through prioritization of high-resolution testing or isolation measures. Targeting highly conserved genomic regions make pan-family assays robust and resilient to mutation. A strategic stockpile of pan-family assays may improve containment of novel diseases before the availability of species-specific assays.
- Open Access
- 8 December 2017
- Published by Springer Nature in Molecular Autism
- Vol. 8 (1) , 64
No preliminary evidence of differences in astrocyte density within the white matter of the dorsolateral prefrontal cortex in autism
While evidence for white matter and astrocytic abnormalities exist in autism, a detailed investigation of astrocytes has not been conducted. Such an investigation is further warranted by an increasing role for neuroinflammation in autism pathogenesis, with astrocytes being key players in this process. We present the first study of astrocyte density and morphology within the white matter of the dorsolateral prefrontal cortex (DLPFC) in individuals with autism. DLPFC formalin-fixed sections containing white matter from individuals with autism (n = 8, age = 4–51 years) and age-matched controls (n = 7, age = 4–46 years) were immunostained for glial fibrillary acidic protein (GFAP). Density of astrocytes and other glia were estimated via the optical fractionator, astrocyte somal size estimated via the nucleator, and astrocyte process length via the spaceballs probe. We found no evidence for alteration in astrocyte density within DLPFC white matter of individuals with autism versus controls, together with no differences in astrocyte somal size and process length. Our results suggest that astrocyte abnormalities within the white matter in the DLPFC in autism may be less pronounced than previously thought. However, astrocytic dysregulation may still exist in autism, even in the absence of gross morphological changes. Our lack of evidence for astrocyte abnormalities could have been confounded to an extent by having a small sample size and wide age range, with pathological features potentially restricted to early stages of autism. Nonetheless, future investigations would benefit from assessing functional markers of astrocytes in light of the underlying pathophysiology of autism.
- 8 December 2017
- Published by Springer Nature in Molecular Autism
- Vol. 8 (1) , 64
Open AccessNo preliminary evidence of differences in astrocyte density within the white matter of the dorsolateral prefrontal cortex in autism
While evidence for white matter and astrocytic abnormalities exist in autism, a detailed investigation of astrocytes has not been conducted. Such an investigation is further warranted by an increasing role for neuroinflammation in autism pathogenesis, with astrocytes being key players in this process. We present the first study of astrocyte density and morphology within the white matter of the dorsolateral prefrontal cortex (DLPFC) in individuals with autism. DLPFC formalin-fixed sections containing white matter from individuals with autism (n = 8, age = 4–51 years) and age-matched controls (n = 7, age = 4–46 years) were immunostained for glial fibrillary acidic protein (GFAP). Density of astrocytes and other glia were estimated via the optical fractionator, astrocyte somal size estimated via the nucleator, and astrocyte process length via the spaceballs probe. We found no evidence for alteration in astrocyte density within DLPFC white matter of individuals with autism versus controls, together with no differences in astrocyte somal size and process length. Our results suggest that astrocyte abnormalities within the white matter in the DLPFC in autism may be less pronounced than previously thought. However, astrocytic dysregulation may still exist in autism, even in the absence of gross morphological changes. Our lack of evidence for astrocyte abnormalities could have been confounded to an extent by having a small sample size and wide age range, with pathological features potentially restricted to early stages of autism. Nonetheless, future investigations would benefit from assessing functional markers of astrocytes in light of the underlying pathophysiology of autism.
- 22 August 2015
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 31 (5) , 464-466
Severe intravenous immunoglobulin‐induced hemolysis with pigment nephropathy managed with red cell exchange
We report on the use of red cell exchange in a case of severe intravenous immune globulin induced hemolysis and pigment nephropathy. Renal impairment and hemoglobinuria were not ameliorated by supportive measures including hydration. Partial red cell exchange with group O blood reduced hemoglobinuria and appeared to stabilize renal function. This is the first report on the use of red cell exchange in this clinical setting. J. Clin. Apheresis 31:464–466, 2016.
- 22 August 2015
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 31 (5) , 464-466
Severe intravenous immunoglobulin‐induced hemolysis with pigment nephropathy managed with red cell exchange
We report on the use of red cell exchange in a case of severe intravenous immune globulin induced hemolysis and pigment nephropathy. Renal impairment and hemoglobinuria were not ameliorated by supportive measures including hydration. Partial red cell exchange with group O blood reduced hemoglobinuria and appeared to stabilize renal function. This is the first report on the use of red cell exchange in this clinical setting. J. Clin. Apheresis 31:464–466, 2016.